References
Innovation in wound care products: a FDA regulatory perspective
The US Food and Drug Administration (FDA) recognises the importance of bringing high-quality, innovative wound care products to the market. This editorial focuses on how the Center for Devices and Radiological Health (CDRH) reviews and supports the development of new devices for wound care. Note that the FDA may regulate a wound care product as a drug, device, biological product or combination product.1 Generally, drugs are reviewed in the Center for Drug Evaluation and Research (CDER), devices are reviewed in the Center for Devices and Radiological Health (CDRH) and biological products are reviewed in the Center for Biologics Evaluation and Research (CBER). A combination product is a product composed of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, a device and a biological product.2,3 If the classification of a product as a drug, device, biological product or combination product is unclear or in dispute, the Office of Combination Products (OCP) assigns the lead agency centre for the product's premarket review and regulation.1
Register now to continue reading
Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Access to clinical or professional articles
-
New content and clinical updates each month